| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| In Situ Hybridization, Fluorescence | 52 | 2022 | 2524 | 2.290 |
Why?
|
| Proto-Oncogene Proteins c-met | 16 | 2020 | 567 | 2.270 |
Why?
|
| Lung Neoplasms | 72 | 2023 | 13576 | 2.180 |
Why?
|
| Pyrazoles | 22 | 2019 | 2021 | 2.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 40 | 2023 | 5422 | 2.030 |
Why?
|
| Gene Amplification | 26 | 2024 | 1090 | 1.880 |
Why?
|
| Pyridines | 22 | 2021 | 2889 | 1.870 |
Why?
|
| Gene Rearrangement | 20 | 2019 | 1139 | 1.830 |
Why?
|
| Isocitrate Dehydrogenase | 23 | 2019 | 954 | 1.820 |
Why?
|
| Mutation | 129 | 2024 | 30230 | 1.780 |
Why?
|
| Gene Fusion | 11 | 2024 | 356 | 1.770 |
Why?
|
| Adenocarcinoma | 34 | 2019 | 6404 | 1.610 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 29 | 2022 | 1628 | 1.610 |
Why?
|
| Protein Kinase Inhibitors | 48 | 2023 | 5707 | 1.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 29 | 2024 | 3666 | 1.550 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2019 | 2433 | 1.500 |
Why?
|
| Drug Resistance, Neoplasm | 35 | 2024 | 5335 | 1.270 |
Why?
|
| Antibodies, Viral | 12 | 2024 | 3211 | 1.190 |
Why?
|
| Bile Duct Neoplasms | 9 | 2023 | 616 | 1.130 |
Why?
|
| Cholangiocarcinoma | 9 | 2023 | 562 | 1.120 |
Why?
|
| Brain Neoplasms | 28 | 2021 | 9197 | 1.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 25 | 2023 | 1765 | 0.980 |
Why?
|
| Oncogene Proteins, Fusion | 16 | 2024 | 1614 | 0.950 |
Why?
|
| Proto-Oncogene Proteins B-raf | 22 | 2023 | 2058 | 0.930 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2019 | 4526 | 0.900 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2024 | 300 | 0.860 |
Why?
|
| Glioblastoma | 16 | 2021 | 3526 | 0.840 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 5 | 2024 | 259 | 0.830 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2017 | 526 | 0.810 |
Why?
|
| Glioma | 16 | 2019 | 3526 | 0.810 |
Why?
|
| DNA Mutational Analysis | 29 | 2020 | 4120 | 0.780 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 18 | 2020 | 906 | 0.740 |
Why?
|
| Oligodendroglioma | 6 | 2019 | 278 | 0.740 |
Why?
|
| Genes, erbB-1 | 7 | 2017 | 163 | 0.740 |
Why?
|
| Glutarates | 7 | 2018 | 243 | 0.720 |
Why?
|
| Neoplasms | 22 | 2024 | 22389 | 0.710 |
Why?
|
| Gene Products, nef | 9 | 2000 | 102 | 0.700 |
Why?
|
| Neoplastic Cells, Circulating | 9 | 2023 | 957 | 0.610 |
Why?
|
| Receptors, Growth Factor | 4 | 2011 | 326 | 0.590 |
Why?
|
| Humans | 292 | 2024 | 768298 | 0.590 |
Why?
|
| Genetic Testing | 6 | 2019 | 3587 | 0.580 |
Why?
|
| Genomics | 6 | 2023 | 5916 | 0.570 |
Why?
|
| Aged, 80 and over | 69 | 2024 | 59683 | 0.550 |
Why?
|
| Quinazolines | 8 | 2016 | 1374 | 0.550 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2014 | 755 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 15 | 2020 | 2830 | 0.540 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2015 | 187 | 0.540 |
Why?
|
| Middle Aged | 137 | 2024 | 223463 | 0.540 |
Why?
|
| Receptor, trkA | 4 | 2019 | 159 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 710 | 0.520 |
Why?
|
| Mosaicism | 3 | 2021 | 481 | 0.520 |
Why?
|
| Chordoma | 3 | 2019 | 349 | 0.520 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2023 | 304 | 0.510 |
Why?
|
| Molecular Diagnostic Techniques | 7 | 2019 | 620 | 0.510 |
Why?
|
| Female | 175 | 2024 | 397050 | 0.500 |
Why?
|
| Antineoplastic Agents | 25 | 2023 | 13696 | 0.500 |
Why?
|
| Simian immunodeficiency virus | 9 | 2000 | 814 | 0.500 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 5 | 2024 | 213 | 0.500 |
Why?
|
| Immunohistochemistry | 30 | 2024 | 11117 | 0.490 |
Why?
|
| Aged | 114 | 2024 | 171544 | 0.490 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2021 | 218 | 0.490 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 452 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2022 | 9433 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2019 | 350 | 0.480 |
Why?
|
| Genes, ras | 5 | 2015 | 665 | 0.470 |
Why?
|
| Genotype | 26 | 2021 | 13038 | 0.470 |
Why?
|
| Gene Dosage | 7 | 2013 | 1221 | 0.470 |
Why?
|
| Lactams, Macrocyclic | 5 | 2018 | 319 | 0.470 |
Why?
|
| ras Proteins | 14 | 2015 | 1058 | 0.460 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 83 | 0.460 |
Why?
|
| DNA, Neoplasm | 11 | 2019 | 1748 | 0.450 |
Why?
|
| Genes, Neoplasm | 3 | 2014 | 370 | 0.450 |
Why?
|
| Translocation, Genetic | 6 | 2022 | 1395 | 0.450 |
Why?
|
| Receptor, erbB-2 | 11 | 2024 | 2588 | 0.450 |
Why?
|
| Gallbladder Neoplasms | 2 | 2014 | 191 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 6 | 2024 | 2006 | 0.440 |
Why?
|
| Adult | 104 | 2024 | 223622 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2019 | 640 | 0.440 |
Why?
|
| Phosphatidylinositol 3-Kinases | 14 | 2018 | 2884 | 0.440 |
Why?
|
| Male | 144 | 2024 | 364870 | 0.430 |
Why?
|
| Exons | 2 | 2016 | 2392 | 0.430 |
Why?
|
| DNA Copy Number Variations | 9 | 2024 | 2046 | 0.420 |
Why?
|
| Esophageal Neoplasms | 5 | 2020 | 1675 | 0.420 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 405 | 0.420 |
Why?
|
| Salivary Gland Neoplasms | 4 | 2024 | 306 | 0.420 |
Why?
|
| Breast Neoplasms | 16 | 2024 | 21163 | 0.410 |
Why?
|
| Cell Line, Tumor | 36 | 2021 | 17132 | 0.410 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2011 | 368 | 0.410 |
Why?
|
| Chromosome Deletion | 5 | 2019 | 1390 | 0.390 |
Why?
|
| Chromosome Aberrations | 3 | 2018 | 1780 | 0.390 |
Why?
|
| RNA-Binding Protein EWS | 4 | 2021 | 211 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 4069 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11854 | 0.390 |
Why?
|
| Comparative Genomic Hybridization | 5 | 2019 | 474 | 0.390 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1238 | 0.380 |
Why?
|
| Aneuploidy | 2 | 2019 | 572 | 0.380 |
Why?
|
| Wilms Tumor | 3 | 2013 | 379 | 0.380 |
Why?
|
| Genome, Human | 7 | 2021 | 4450 | 0.380 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 1481 | 0.380 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2009 | 89 | 0.370 |
Why?
|
| Prognosis | 30 | 2024 | 30020 | 0.370 |
Why?
|
| DNA Methylation | 9 | 2021 | 4419 | 0.370 |
Why?
|
| Sequence Analysis, DNA | 11 | 2021 | 4774 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 6 | 2015 | 5443 | 0.360 |
Why?
|
| Papillomavirus Infections | 5 | 2023 | 1640 | 0.360 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 39 | 0.350 |
Why?
|
| Genetic Variation | 7 | 2017 | 6606 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2023 | 2950 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 13 | 2021 | 6084 | 0.350 |
Why?
|
| Oncogene Fusion | 5 | 2019 | 83 | 0.350 |
Why?
|
| Odontogenic Tumors | 2 | 2021 | 48 | 0.340 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2015 | 450 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2024 | 8628 | 0.340 |
Why?
|
| Liver Neoplasms | 9 | 2017 | 4360 | 0.340 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2024 | 264 | 0.330 |
Why?
|
| Carcinoma, Papillary | 3 | 2016 | 793 | 0.330 |
Why?
|
| Melanoma | 4 | 2023 | 5705 | 0.330 |
Why?
|
| Uterine Neoplasms | 3 | 2018 | 1426 | 0.320 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 1118 | 0.320 |
Why?
|
| Medical Informatics | 1 | 2016 | 739 | 0.320 |
Why?
|
| Receptor, trkC | 2 | 2019 | 63 | 0.320 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 683 | 0.320 |
Why?
|
| Hydatidiform Mole | 1 | 2011 | 255 | 0.320 |
Why?
|
| Chromosomes, Human, X | 2 | 2007 | 320 | 0.310 |
Why?
|
| Immunity, Humoral | 2 | 2024 | 611 | 0.310 |
Why?
|
| Thyroid Neoplasms | 5 | 2024 | 2360 | 0.310 |
Why?
|
| Genetic Heterogeneity | 5 | 2019 | 737 | 0.310 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 99 | 0.290 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2018 | 388 | 0.290 |
Why?
|
| Disease Progression | 16 | 2023 | 13646 | 0.290 |
Why?
|
| Chimera | 1 | 2009 | 454 | 0.290 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2020 | 959 | 0.290 |
Why?
|
| Gene Deletion | 3 | 2019 | 2673 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2019 | 228 | 0.280 |
Why?
|
| Neoplasm Staging | 15 | 2019 | 11254 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2007 | 247 | 0.280 |
Why?
|
| Bile Ducts | 2 | 2020 | 287 | 0.270 |
Why?
|
| Acrylamides | 3 | 2018 | 260 | 0.270 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2023 | 493 | 0.270 |
Why?
|
| Microsatellite Instability | 6 | 2014 | 726 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2018 | 2811 | 0.270 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 5857 | 0.270 |
Why?
|
| Eosinophilia | 2 | 2022 | 556 | 0.260 |
Why?
|
| Dacarbazine | 4 | 2017 | 560 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2020 | 3616 | 0.260 |
Why?
|
| Sequence Analysis, RNA | 4 | 2024 | 2038 | 0.260 |
Why?
|
| Immunoglobulin M | 5 | 2020 | 1528 | 0.250 |
Why?
|
| MAP Kinase Kinase 1 | 6 | 2017 | 331 | 0.250 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 4 | 2019 | 109 | 0.240 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 4921 | 0.240 |
Why?
|
| Young Adult | 34 | 2024 | 60048 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2014 | 6541 | 0.230 |
Why?
|
| Carcinoma | 4 | 2023 | 2340 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2024 | 82 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 7 | 2019 | 5800 | 0.230 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 358 | 0.230 |
Why?
|
| Pyrimidines | 9 | 2020 | 3048 | 0.230 |
Why?
|
| Polymorphism, Genetic | 3 | 2011 | 4250 | 0.220 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 2923 | 0.220 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 376 | 0.220 |
Why?
|
| Smad4 Protein | 4 | 2020 | 193 | 0.220 |
Why?
|
| Disease-Free Survival | 9 | 2018 | 6856 | 0.210 |
Why?
|
| Carcinoma in Situ | 3 | 2023 | 789 | 0.210 |
Why?
|
| Molecular Probes | 2 | 2019 | 309 | 0.210 |
Why?
|
| Colonic Neoplasms | 5 | 2018 | 2542 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 3811 | 0.210 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 622 | 0.200 |
Why?
|
| Sensitivity and Specificity | 10 | 2024 | 14736 | 0.200 |
Why?
|
| Software | 1 | 2016 | 4452 | 0.200 |
Why?
|
| Smoking | 7 | 2019 | 9109 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2022 | 3620 | 0.200 |
Why?
|
| Pancreatic Cyst | 2 | 2016 | 369 | 0.200 |
Why?
|
| Meningioma | 2 | 2022 | 1221 | 0.190 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 3 | 2017 | 85 | 0.190 |
Why?
|
| Pharmacy | 1 | 2023 | 92 | 0.190 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2022 | 91 | 0.190 |
Why?
|
| Meningeal Neoplasms | 2 | 2022 | 1253 | 0.190 |
Why?
|
| GTP Phosphohydrolases | 5 | 2016 | 525 | 0.190 |
Why?
|
| Bone Cysts | 1 | 2021 | 48 | 0.180 |
Why?
|
| Benzimidazoles | 3 | 2019 | 864 | 0.180 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 102 | 0.180 |
Why?
|
| Retrospective Studies | 31 | 2024 | 81768 | 0.180 |
Why?
|
| Colorectal Neoplasms | 6 | 2018 | 6969 | 0.180 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2021 | 67 | 0.180 |
Why?
|
| Signal Transduction | 19 | 2020 | 23629 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 749 | 0.180 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2023 | 243 | 0.180 |
Why?
|
| Nanopores | 1 | 2021 | 48 | 0.180 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2019 | 125 | 0.180 |
Why?
|
| Craniopharyngioma | 1 | 2023 | 279 | 0.180 |
Why?
|
| Thoracic Neoplasms | 1 | 2023 | 269 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2017 | 618 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 997 | 0.170 |
Why?
|
| Cohort Studies | 18 | 2024 | 41791 | 0.170 |
Why?
|
| Survival Rate | 13 | 2020 | 12870 | 0.170 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2023 | 290 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 2066 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 1408 | 0.170 |
Why?
|
| Immunologic Tests | 1 | 2020 | 104 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 3 | 2019 | 580 | 0.170 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 92 | 0.170 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2015 | 736 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5375 | 0.170 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 238 | 0.170 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 179 | 0.170 |
Why?
|
| Septins | 1 | 2019 | 49 | 0.170 |
Why?
|
| Chromogranins | 2 | 2017 | 160 | 0.170 |
Why?
|
| Astrocytoma | 4 | 2013 | 780 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 1492 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2015 | 1756 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 183 | 0.160 |
Why?
|
| Telomerase | 3 | 2018 | 752 | 0.160 |
Why?
|
| Down-Regulation | 7 | 2000 | 2937 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 218 | 0.160 |
Why?
|
| RNA Helicases | 1 | 2020 | 144 | 0.160 |
Why?
|
| DNA-Binding Proteins | 9 | 2022 | 9618 | 0.160 |
Why?
|
| Humerus | 1 | 2021 | 273 | 0.160 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2018 | 20 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 2 | 2017 | 538 | 0.160 |
Why?
|
| Base Sequence | 8 | 2015 | 12421 | 0.160 |
Why?
|
| Mesothelioma | 1 | 2015 | 811 | 0.160 |
Why?
|
| NFATC Transcription Factors | 1 | 2021 | 393 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2019 | 2461 | 0.160 |
Why?
|
| Jaw Neoplasms | 1 | 2019 | 72 | 0.160 |
Why?
|
| Receptor, trkB | 1 | 2019 | 125 | 0.160 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 2429 | 0.160 |
Why?
|
| Genes, erbB-2 | 3 | 2017 | 162 | 0.160 |
Why?
|
| Fibula | 1 | 2021 | 270 | 0.150 |
Why?
|
| Antibody Specificity | 1 | 2020 | 1065 | 0.150 |
Why?
|
| Immunoglobulin G | 5 | 2020 | 4570 | 0.150 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 20224 | 0.150 |
Why?
|
| Virion | 1 | 2000 | 430 | 0.150 |
Why?
|
| Thrombocytosis | 1 | 2018 | 88 | 0.150 |
Why?
|
| Cyst Fluid | 2 | 2016 | 83 | 0.150 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2017 | 195 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 314 | 0.150 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 131 | 0.150 |
Why?
|
| Neuregulin-1 | 2 | 2017 | 136 | 0.150 |
Why?
|
| Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2014 | 2911 | 0.150 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 3722 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 354 | 0.150 |
Why?
|
| Fingers | 1 | 2021 | 512 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 117 | 0.150 |
Why?
|
| Color | 1 | 2019 | 297 | 0.150 |
Why?
|
| Parotid Neoplasms | 1 | 2019 | 158 | 0.150 |
Why?
|
| Transcription Factors | 9 | 2022 | 12166 | 0.150 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 1158 | 0.150 |
Why?
|
| NAD | 3 | 2017 | 618 | 0.150 |
Why?
|
| Gene Expression Profiling | 9 | 2017 | 9508 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2014 | 720 | 0.150 |
Why?
|
| Treatment Outcome | 18 | 2020 | 65365 | 0.150 |
Why?
|
| Guanidines | 1 | 2018 | 194 | 0.140 |
Why?
|
| Adenofibroma | 1 | 2017 | 25 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 827 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 410 | 0.140 |
Why?
|
| Carbazoles | 2 | 2019 | 221 | 0.140 |
Why?
|
| Cytogenetic Analysis | 4 | 2018 | 270 | 0.140 |
Why?
|
| Phenylurea Compounds | 2 | 2019 | 529 | 0.140 |
Why?
|
| Dystrophin | 1 | 2018 | 284 | 0.140 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2017 | 43 | 0.140 |
Why?
|
| Transcription Factors, TFII | 1 | 1997 | 62 | 0.140 |
Why?
|
| Barrett Esophagus | 2 | 2011 | 494 | 0.140 |
Why?
|
| Immunoassay | 1 | 2020 | 744 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2017 | 930 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 623 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2022 | 596 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 3781 | 0.140 |
Why?
|
| Codon | 3 | 2014 | 599 | 0.130 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2016 | 62 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2021 | 644 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 790 | 0.130 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2565 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 4 | 2017 | 1356 | 0.130 |
Why?
|
| Karyotyping | 2 | 2009 | 1173 | 0.130 |
Why?
|
| Fibrosarcoma | 1 | 2018 | 313 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2021 | 707 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 954 | 0.130 |
Why?
|
| Piperidines | 4 | 2020 | 1660 | 0.130 |
Why?
|
| src Homology Domains | 4 | 2007 | 361 | 0.130 |
Why?
|
| HIV-1 | 7 | 2000 | 6963 | 0.130 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Cell Proliferation | 9 | 2020 | 10464 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 342 | 0.130 |
Why?
|
| Mice, SCID | 5 | 2019 | 2632 | 0.130 |
Why?
|
| Point Mutation | 4 | 2016 | 1595 | 0.130 |
Why?
|
| Aniline Compounds | 2 | 2018 | 1094 | 0.120 |
Why?
|
| Phosphoproteins | 3 | 2018 | 2448 | 0.120 |
Why?
|
| Lectins, C-Type | 2 | 2015 | 591 | 0.120 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 7 | 2000 | 149 | 0.120 |
Why?
|
| beta Catenin | 4 | 2014 | 1047 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 802 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 937 | 0.120 |
Why?
|
| Tropomyosin | 1 | 2015 | 106 | 0.120 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 3436 | 0.120 |
Why?
|
| Genes, nef | 3 | 2000 | 52 | 0.120 |
Why?
|
| Biliary Tract | 1 | 2015 | 135 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2015 | 1399 | 0.120 |
Why?
|
| Massachusetts | 4 | 2020 | 8902 | 0.120 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 317 | 0.120 |
Why?
|
| Workflow | 2 | 2017 | 859 | 0.120 |
Why?
|
| Prospective Studies | 17 | 2022 | 54921 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2023 | 1325 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 1105 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2015 | 575 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2014 | 4043 | 0.120 |
Why?
|
| Femur | 1 | 2021 | 1311 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2020 | 853 | 0.120 |
Why?
|
| Esophagogastric Junction | 2 | 2020 | 349 | 0.120 |
Why?
|
| Cecal Neoplasms | 1 | 2014 | 27 | 0.120 |
Why?
|
| Mice | 22 | 2020 | 82004 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3609 | 0.110 |
Why?
|
| Liver Circulation | 1 | 2014 | 158 | 0.110 |
Why?
|
| Gene Expression | 8 | 2018 | 7595 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 6132 | 0.110 |
Why?
|
| Benzoquinones | 2 | 2014 | 198 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 425 | 0.110 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2014 | 59 | 0.110 |
Why?
|
| Pathology, Molecular | 2 | 2014 | 329 | 0.110 |
Why?
|
| Phenotype | 14 | 2019 | 16716 | 0.110 |
Why?
|
| Indazoles | 1 | 2015 | 305 | 0.110 |
Why?
|
| Animals | 35 | 2024 | 169322 | 0.110 |
Why?
|
| Molecular Sequence Data | 12 | 2015 | 17626 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 4301 | 0.110 |
Why?
|
| Nuclear Proteins | 5 | 2022 | 5802 | 0.110 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2012 | 85 | 0.110 |
Why?
|
| Papillomaviridae | 4 | 2023 | 1140 | 0.110 |
Why?
|
| Medical Oncology | 3 | 2023 | 2348 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 216 | 0.110 |
Why?
|
| Adolescent | 19 | 2023 | 89182 | 0.110 |
Why?
|
| Receptors, Estrogen | 4 | 2024 | 2247 | 0.110 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Hepatoblastoma | 1 | 2013 | 90 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 196 | 0.110 |
Why?
|
| Aminopyridines | 4 | 2018 | 580 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 871 | 0.100 |
Why?
|
| Biopsy | 7 | 2020 | 6808 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 2003 | 0.100 |
Why?
|
| Apocrine Glands | 1 | 2012 | 31 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3118 | 0.100 |
Why?
|
| Mice, Nude | 5 | 2020 | 3630 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2020 | 4584 | 0.100 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 520 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2000 | 1362 | 0.100 |
Why?
|
| Oncogenes | 3 | 2014 | 1234 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3241 | 0.100 |
Why?
|
| Lung | 3 | 2018 | 10087 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2018 | 614 | 0.100 |
Why?
|
| Eccrine Glands | 1 | 2012 | 52 | 0.100 |
Why?
|
| Carcinoma, Ductal | 1 | 2012 | 97 | 0.100 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2013 | 125 | 0.100 |
Why?
|
| Blotting, Western | 6 | 2017 | 5033 | 0.100 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 39405 | 0.100 |
Why?
|
| Single-Cell Analysis | 3 | 2022 | 2533 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 2 | 2011 | 2709 | 0.100 |
Why?
|
| DNA Repair Enzymes | 4 | 2018 | 346 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 637 | 0.100 |
Why?
|
| Lactams | 3 | 2018 | 159 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 1902 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2014 | 423 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3631 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 521 | 0.100 |
Why?
|
| Databases, Genetic | 2 | 2019 | 1748 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2007 | 1305 | 0.090 |
Why?
|
| Pulmonary Circulation | 1 | 2014 | 744 | 0.090 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 34 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2013 | 255 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 673 | 0.090 |
Why?
|
| Survival Analysis | 7 | 2020 | 10117 | 0.090 |
Why?
|
| Graft Survival | 2 | 2015 | 3900 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2020 | 6350 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 1438 | 0.090 |
Why?
|
| DNA, Satellite | 1 | 2011 | 67 | 0.090 |
Why?
|
| Membrane Proteins | 8 | 2016 | 7885 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1428 | 0.090 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 13019 | 0.090 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 1926 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 6 | 2015 | 9261 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 12092 | 0.090 |
Why?
|
| Amino Acid Sequence | 9 | 2015 | 13425 | 0.090 |
Why?
|
| Drug Resistance | 2 | 2014 | 1595 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 677 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2014 | 887 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 636 | 0.090 |
Why?
|
| Radiography | 3 | 2011 | 6993 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2014 | 433 | 0.090 |
Why?
|
| DNA Probes | 1 | 2011 | 542 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 2014 | 506 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 310 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2010 | 108 | 0.090 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 615 | 0.090 |
Why?
|
| Gliosis | 1 | 2011 | 246 | 0.090 |
Why?
|
| Benzamides | 1 | 2015 | 1380 | 0.080 |
Why?
|
| Virus Replication | 5 | 2000 | 2458 | 0.080 |
Why?
|
| Sequence Deletion | 3 | 2013 | 1496 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1410 | 0.080 |
Why?
|
| Tumor Burden | 4 | 2017 | 1913 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 2003 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 693 | 0.080 |
Why?
|
| Radiology | 1 | 2023 | 2117 | 0.080 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2011 | 111 | 0.080 |
Why?
|
| Piperazines | 4 | 2021 | 2552 | 0.080 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 590 | 0.080 |
Why?
|
| Germinal Center | 1 | 2011 | 380 | 0.080 |
Why?
|
| DNA Modification Methylases | 3 | 2018 | 209 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 731 | 0.080 |
Why?
|
| Sulfones | 3 | 2016 | 448 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1614 | 0.080 |
Why?
|
| Pancreas | 1 | 2015 | 1701 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2012 | 573 | 0.080 |
Why?
|
| Medulloblastoma | 1 | 2014 | 682 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 1382 | 0.080 |
Why?
|
| Cross Reactions | 2 | 2020 | 828 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 3712 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 2986 | 0.080 |
Why?
|
| Eligibility Determination | 1 | 2012 | 421 | 0.080 |
Why?
|
| Algorithms | 2 | 2019 | 14154 | 0.080 |
Why?
|
| Aspirin | 1 | 2020 | 3136 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 566 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2023 | 3627 | 0.080 |
Why?
|
| Adenomatous Polyps | 1 | 2009 | 109 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 749 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2012 | 460 | 0.070 |
Why?
|
| Carboplatin | 1 | 2011 | 799 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2018 | 964 | 0.070 |
Why?
|
| Kidney Transplantation | 2 | 2015 | 4300 | 0.070 |
Why?
|
| Phosphorylation | 7 | 2015 | 8326 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2012 | 1420 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2017 | 1346 | 0.070 |
Why?
|
| Research | 1 | 2016 | 1981 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1997 | 2568 | 0.070 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2009 | 118 | 0.070 |
Why?
|
| Genes, p16 | 2 | 2020 | 160 | 0.070 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 10266 | 0.070 |
Why?
|
| Gene Frequency | 4 | 2015 | 3615 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2012 | 330 | 0.070 |
Why?
|
| Pneumonectomy | 1 | 2014 | 1158 | 0.070 |
Why?
|
| Advisory Committees | 1 | 2011 | 797 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 3940 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2011 | 457 | 0.070 |
Why?
|
| Founder Effect | 1 | 2007 | 185 | 0.070 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2007 | 112 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2019 | 239 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2014 | 1093 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2014 | 2929 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 2020 | 991 | 0.070 |
Why?
|
| Genes, Wilms Tumor | 1 | 2007 | 92 | 0.070 |
Why?
|
| Sarcoma | 1 | 2018 | 1806 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1881 | 0.070 |
Why?
|
| DNA Primers | 3 | 2021 | 2823 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 640 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2007 | 1473 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 1060 | 0.070 |
Why?
|
| Fractures, Compression | 1 | 2008 | 132 | 0.070 |
Why?
|
| Spheroids, Cellular | 2 | 2020 | 331 | 0.070 |
Why?
|
| Mesoderm | 1 | 2009 | 679 | 0.070 |
Why?
|
| Pandemics | 3 | 2021 | 8750 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 24 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2018 | 12801 | 0.070 |
Why?
|
| Autopsy | 3 | 2019 | 1013 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 16027 | 0.070 |
Why?
|
| Brain | 4 | 2021 | 27452 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 20766 | 0.070 |
Why?
|
| Child | 11 | 2022 | 80894 | 0.060 |
Why?
|
| Thrombosis | 1 | 2020 | 2955 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2008 | 577 | 0.060 |
Why?
|
| Telemedicine | 1 | 2023 | 3107 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2008 | 266 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2014 | 1412 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2018 | 200 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 2819 | 0.060 |
Why?
|
| Endonucleases | 1 | 2008 | 371 | 0.060 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2000 | 545 | 0.060 |
Why?
|
| Time Factors | 9 | 2024 | 40267 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4286 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2023 | 2205 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 3779 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 4 | 2000 | 303 | 0.060 |
Why?
|
| Adaptor Protein Complex alpha Subunits | 3 | 2000 | 23 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1078 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 1026 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 641 | 0.060 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2014 | 945 | 0.060 |
Why?
|
| Tyrosine | 5 | 2000 | 1428 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 596 | 0.060 |
Why?
|
| Cytokines | 2 | 2020 | 7443 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 945 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 1185 | 0.060 |
Why?
|
| Hyperplasia | 2 | 2023 | 1152 | 0.060 |
Why?
|
| Computational Biology | 3 | 2019 | 3541 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2016 | 338 | 0.060 |
Why?
|
| Genes, Duplicate | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 5538 | 0.060 |
Why?
|
| Back Pain | 1 | 2008 | 547 | 0.060 |
Why?
|
| Glucose | 1 | 2016 | 4354 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2015 | 3585 | 0.060 |
Why?
|
| Jurkat Cells | 4 | 1999 | 738 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 18047 | 0.060 |
Why?
|
| COS Cells | 4 | 2000 | 1135 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1542 | 0.060 |
Why?
|
| Cell Survival | 4 | 2016 | 5792 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2015 | 1837 | 0.060 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2024 | 196 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3457 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 3826 | 0.060 |
Why?
|
| Thoracic Vertebrae | 1 | 2008 | 613 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2015 | 2749 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2017 | 2574 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2060 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 2019 | 1337 | 0.050 |
Why?
|
| Viral Load | 3 | 2022 | 3398 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 1743 | 0.050 |
Why?
|
| RNA Editing | 2 | 2014 | 149 | 0.050 |
Why?
|
| Quinazolinones | 2 | 2019 | 219 | 0.050 |
Why?
|
| Adenoma | 1 | 2014 | 2163 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2016 | 2293 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2008 | 748 | 0.050 |
Why?
|
| Macaca mulatta | 5 | 2000 | 2361 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2015 | 2177 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2023 | 150 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 525 | 0.050 |
Why?
|
| Pyrroles | 1 | 2009 | 1126 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2006 | 540 | 0.050 |
Why?
|
| K562 Cells | 2 | 2018 | 637 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2008 | 936 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 605 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 3794 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2007 | 2342 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 330 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 185 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 1349 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2014 | 466 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4273 | 0.050 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2021 | 166 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2008 | 712 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2020 | 2887 | 0.050 |
Why?
|
| Kidney | 2 | 2015 | 7063 | 0.050 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 6670 | 0.050 |
Why?
|
| Cell Movement | 3 | 2015 | 5214 | 0.050 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 15455 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 18358 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 292 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2024 | 376 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2019 | 3060 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1825 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3471 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 378 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2021 | 190 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2015 | 5408 | 0.040 |
Why?
|
| Electroporation | 1 | 2021 | 236 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 4859 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2007 | 1501 | 0.040 |
Why?
|
| Protein Conformation | 3 | 2014 | 3957 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2021 | 231 | 0.040 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 12557 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2016 | 8072 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 101 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 10656 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2008 | 1265 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2021 | 42654 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1866 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 525 | 0.040 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2593 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 372 | 0.040 |
Why?
|
| HIV Long-Term Survivors | 1 | 2000 | 140 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2020 | 273 | 0.040 |
Why?
|
| Sex Chromatin | 1 | 2018 | 19 | 0.040 |
Why?
|
| Metabolomics | 2 | 2020 | 1675 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1907 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 391 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1943 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2011 | 4505 | 0.040 |
Why?
|
| Astrocytes | 1 | 2006 | 1349 | 0.040 |
Why?
|
| Pyridazines | 1 | 2020 | 204 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4647 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 178 | 0.040 |
Why?
|
| Biotechnology | 1 | 2020 | 283 | 0.040 |
Why?
|
| Ethylnitrosourea | 1 | 2018 | 50 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 2331 | 0.040 |
Why?
|
| Haploidy | 1 | 2018 | 127 | 0.040 |
Why?
|
| Calcitonin | 1 | 2019 | 329 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 156 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2016 | 11659 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 662 | 0.040 |
Why?
|
| Pyridones | 2 | 2017 | 818 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 1647 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 556 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2018 | 162 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1104 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2020 | 715 | 0.040 |
Why?
|
| United States | 2 | 2024 | 73144 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 614 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2022 | 992 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2009 | 3692 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2012 | 725 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 444 | 0.040 |
Why?
|
| Phthalazines | 1 | 2020 | 397 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.040 |
Why?
|
| Remission Induction | 1 | 2023 | 2407 | 0.040 |
Why?
|
| Capillaries | 1 | 2020 | 756 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2009 | 432 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 205 | 0.040 |
Why?
|
| Transcription Factor TFIIIA | 1 | 2016 | 24 | 0.040 |
Why?
|
| Transcription Factor TFIIH | 1 | 1997 | 33 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2017 | 2664 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2017 | 156 | 0.040 |
Why?
|
| Risk Factors | 7 | 2023 | 74954 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2017 | 165 | 0.030 |
Why?
|
| Binding Sites | 4 | 2015 | 6018 | 0.030 |
Why?
|
| E2F Transcription Factors | 1 | 2017 | 270 | 0.030 |
Why?
|
| Virulence | 1 | 2000 | 1298 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1999 | 435 | 0.030 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 8051 | 0.030 |
Why?
|
| Cell Line | 3 | 2020 | 15593 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 691 | 0.030 |
Why?
|
| Plasmids | 1 | 2021 | 2267 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2018 | 424 | 0.030 |
Why?
|
| Veins | 1 | 2020 | 768 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 863 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 890 | 0.030 |
Why?
|
| Epitopes | 1 | 2022 | 2525 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2015 | 62 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2021 | 1153 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2006 | 3442 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 10776 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2021 | 1337 | 0.030 |
Why?
|
| Age Factors | 2 | 2009 | 18472 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 5758 | 0.030 |
Why?
|
| Alleles | 4 | 2015 | 6892 | 0.030 |
Why?
|
| Cystadenoma | 1 | 2015 | 77 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1145 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 386 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2017 | 453 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 295 | 0.030 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2015 | 69 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2014 | 66 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2298 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1997 | 896 | 0.030 |
Why?
|
| Colon, Ascending | 1 | 2014 | 14 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2016 | 256 | 0.030 |
Why?
|
| Breast | 1 | 2023 | 1975 | 0.030 |
Why?
|
| Purines | 1 | 2018 | 615 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 147 | 0.030 |
Why?
|
| RNA Interference | 2 | 2016 | 2836 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1999 | 1207 | 0.030 |
Why?
|
| Apoptosis | 3 | 2016 | 9506 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 876 | 0.030 |
Why?
|
| Nephritis | 1 | 2015 | 147 | 0.030 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 18 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 563 | 0.030 |
Why?
|
| Kinetics | 1 | 2022 | 6334 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1794 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 833 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 948 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2017 | 805 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 784 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 2236 | 0.030 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 305 | 0.030 |
Why?
|
| Hyperphosphatemia | 1 | 2013 | 38 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 252 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 306 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3440 | 0.030 |
Why?
|
| Pancreatic Ducts | 1 | 2015 | 330 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 14783 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 4076 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2014 | 322 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 353 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 520 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2017 | 588 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2015 | 412 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2014 | 706 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4414 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 182 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3622 | 0.030 |
Why?
|
| Idarubicin | 1 | 2012 | 59 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2012 | 49 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1368 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 2397 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 408 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2022 | 2855 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 504 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 598 | 0.020 |
Why?
|
| Glycolysis | 1 | 2016 | 838 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1019 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2012 | 81 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 2559 | 0.020 |
Why?
|
| Protein Binding | 3 | 2017 | 9346 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2012 | 26410 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2012 | 103 | 0.020 |
Why?
|
| World Health Organization | 1 | 2017 | 1327 | 0.020 |
Why?
|
| Japan | 1 | 2016 | 1418 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2015 | 1884 | 0.020 |
Why?
|
| Valine | 1 | 2013 | 410 | 0.020 |
Why?
|
| Cardia | 1 | 2011 | 61 | 0.020 |
Why?
|
| Tissue Embedding | 1 | 2011 | 43 | 0.020 |
Why?
|
| Vaccination | 1 | 2023 | 3431 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2012 | 148 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2020 | 22292 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1034 | 0.020 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2010 | 17 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1536 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 335 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3553 | 0.020 |
Why?
|
| Mutagenesis | 2 | 2008 | 1229 | 0.020 |
Why?
|
| Neuroglia | 1 | 2016 | 960 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 697 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 11220 | 0.020 |
Why?
|
| DNA Repair | 1 | 2000 | 2050 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 968 | 0.020 |
Why?
|
| Heterozygote | 2 | 2007 | 2792 | 0.020 |
Why?
|
| Culture | 1 | 2014 | 623 | 0.020 |
Why?
|
| Liver | 1 | 2006 | 7570 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 628 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2277 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 669 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2011 | 207 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 665 | 0.020 |
Why?
|
| Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 489 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 842 | 0.020 |
Why?
|
| Patient Selection | 2 | 2012 | 4265 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 36849 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2016 | 4740 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2009 | 144 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 551 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3537 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 223 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2023 | 6277 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 891 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8730 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1141 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 30198 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1760 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2009 | 124 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7211 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2014 | 557 | 0.020 |
Why?
|
| Microfluidics | 1 | 2014 | 674 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 2139 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 2842 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 2068 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 332 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1973 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 190 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1748 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2014 | 2931 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 9063 | 0.020 |
Why?
|
| Cell Separation | 1 | 2014 | 1725 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 2202 | 0.020 |
Why?
|
| Chromatin | 1 | 2020 | 2967 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 306 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 269 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2011 | 294 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1883 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 2097 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2015 | 1894 | 0.020 |
Why?
|
| Microglia | 1 | 2017 | 1374 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 965 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2862 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2909 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1515 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 1265 | 0.020 |
Why?
|
| Autophagy | 1 | 2015 | 1350 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 114 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1855 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2934 | 0.020 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2007 | 34 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1605 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 4981 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2013 | 1193 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1905 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2007 | 265 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3905 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 1666 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2007 | 156 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 617 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2741 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 2180 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1705 | 0.020 |
Why?
|
| C-Peptide | 1 | 2008 | 443 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1727 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2924 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1997 | 4031 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2011 | 4175 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 1684 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 9563 | 0.020 |
Why?
|
| Lymphokines | 1 | 2009 | 927 | 0.020 |
Why?
|
| Asia | 1 | 2007 | 627 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10588 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2006 | 224 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 2076 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1736 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 1208 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 339 | 0.020 |
Why?
|
| Portal Vein | 1 | 2008 | 431 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 1064 | 0.020 |
Why?
|
| Factor V | 1 | 2006 | 168 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1915 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 654 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 770 | 0.020 |
Why?
|
| Endocytosis | 2 | 2000 | 959 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2015 | 1980 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 905 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2008 | 841 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 559 | 0.010 |
Why?
|
| Lectins | 1 | 2006 | 490 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2006 | 525 | 0.010 |
Why?
|
| Adipokines | 1 | 2006 | 309 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2906 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2020 | 4842 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2009 | 942 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2734 | 0.010 |
Why?
|
| Ascites | 1 | 2006 | 338 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2846 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 984 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2008 | 715 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2623 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3236 | 0.010 |
Why?
|
| Acute Disease | 2 | 2012 | 7242 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2007 | 1585 | 0.010 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4908 | 0.010 |
Why?
|
| Atrophy | 1 | 2008 | 1648 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 463 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 1339 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2006 | 561 | 0.010 |
Why?
|
| Aging | 1 | 2022 | 8764 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15939 | 0.010 |
Why?
|
| Motor Neurons | 1 | 2007 | 872 | 0.010 |
Why?
|
| Models, Biological | 1 | 1999 | 9494 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8501 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6238 | 0.010 |
Why?
|
| Ligands | 1 | 2009 | 3283 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5796 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2008 | 2604 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1131 | 0.010 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2008 | 823 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 2417 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26373 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 1526 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2724 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10377 | 0.010 |
Why?
|
| Haloperidol | 1 | 1983 | 394 | 0.010 |
Why?
|
| Antibodies | 1 | 2009 | 2425 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 1885 | 0.010 |
Why?
|
| Mass Screening | 1 | 2017 | 5451 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 1459 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1141 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5898 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 1371 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2006 | 1019 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2010 | 2487 | 0.010 |
Why?
|
| Fetus | 1 | 2007 | 1883 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1999 | 3728 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3048 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5337 | 0.010 |
Why?
|
| London | 1 | 2000 | 233 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2007 | 1813 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2000 | 127 | 0.010 |
Why?
|
| Homosexuality | 1 | 2000 | 268 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 2204 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 866 | 0.010 |
Why?
|
| HLA-B7 Antigen | 1 | 1998 | 48 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2000 | 315 | 0.010 |
Why?
|
| Clathrin | 1 | 1999 | 258 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 928 | 0.010 |
Why?
|
| Macaca | 1 | 1999 | 417 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 1893 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13323 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1980 | 293 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3411 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7599 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1998 | 405 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 1999 | 839 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15868 | 0.010 |
Why?
|
| Surface Properties | 1 | 1999 | 1166 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 3541 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 1684 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 11914 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 3108 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 2750 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3587 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 1997 | 539 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1999 | 2487 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 1980 | 534 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6608 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2000 | 19019 | 0.010 |
Why?
|
| HIV Infections | 1 | 2000 | 17575 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 6001 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 36512 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 24316 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1980 | 1925 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1998 | 3663 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 22355 | 0.000 |
Why?
|
| Schizophrenia | 1 | 1983 | 6987 | 0.000 |
Why?
|
| Prolactin | 1 | 1983 | 626 | 0.000 |
Why?
|
| Myelography | 1 | 1980 | 72 | 0.000 |
Why?
|
| Schizophrenic Psychology | 1 | 1983 | 1652 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1983 | 6034 | 0.000 |
Why?
|